On this page
Quick Reference
Overview and Recommendations
Background
- •Recognize Parkinson disease (PD) as a multisystem alpha-synucleinopathy characterized by the progressive loss of dopaminergic neurons, leading to both classic motor deficits and a wide array of non-motor symptoms (NMS).
- •Identify the clinical phases of the disease, starting with a prodromal phase (hyposmia, constipation, REM sleep behavior disorder) that can precede motor onset by decades, followed by early-stage responsiveness to therapy and late-stage motor complications like (FOG).
- •Understand the shifting diagnostic paradigm toward the SynNeurGe framework, which classifies the disease based on α-synuclein (S), neurodegeneration (N), and genetics (G) rather than purely clinical phenomenology.
- •Note the demographic trends where PD disproportionately affects males (2:1 ratio) and is increasingly prevalent in aging populations, though early-onset Parkinson disease (EOPD) affects those aged 21–50 and often carries a higher genetic burden.
- •Distinguish idiopathic PD from 'Parkinson-plus' syndromes such as (MSA) and (PSP), which typically present with more rapid progression and poor levodopa response.
Evaluation
- •Suspect PD in any patient presenting with asymmetric motor signs, particularly a 4–6 Hz 'pill-rolling' rest tremor, lead-pipe or cogwheel rigidity, or unexplained slowness in activities of daily living.
- •Confirm the presence of bradykinesia, the essential motor sign, by observing a decrement in amplitude or speed during repetitive movements such as finger tapping or rapid alternating hand movements.
- •Perform a Levodopa Challenge by administering a suprathreshold dose (typically 200 mg of levodopa) and measuring the MDS-UPDRS Part III score; a >30% improvement in motor function strongly supports an idiopathic PD diagnosis.
- •Identify 'red flags' that suggest alternative diagnoses, including early severe autonomic failure (orthostatic hypotension), vertical supranuclear gaze palsy, or falls occurring within the first three years of symptom onset.
- •Screen for non-motor features during the clinical encounter, specifically asking about hyposmia (loss of smell), REM sleep behavior disorder (acting out dreams), and chronic constipation.
- •Order a structural MRI to rule out secondary causes such as normal pressure hydrocephalus or vascular , though conventional imaging is often normal in early idiopathic PD.
- •Utilize DaTscan ([123I]FP-CIT SPECT) in cases of clinical uncertainty to visualize striatal dopamine transporter density and confirm a presynaptic dopaminergic deficit.
- •Consider a skin biopsy to detect S129 phospho-α-synuclein (pαSyn) at the C7 and Th12 dermatomes, which can highly accurately differentiate synucleinopathies from tauopathies like PSP.
- •Assess gait and balance using dual-task challenges (e.g., walking while performing mental arithmetic) to reveal impaired motor automaticity and the risk of .
- •Monitor orthostatic blood pressure trajectories longitudinally, as early autonomic failure is a marker for faster disease progression and increased vascular risk.
- •Evaluate for impulse control disorders (ICD) such as pathological gambling or hypersexuality, particularly in patients already receiving dopamine agonist therapy.
Management
- •Administer Carbidopa-Levodopa (e.g., 25/100 mg TID) as the gold standard for motor symptom control, ensuring strict adherence to dosing schedules to avoid 'off' periods.
- •Prioritize medication timing in hospitalized patients; delays or omissions of dopaminergic doses are associated with increased morbidity and mortality in the inpatient setting.
- •Manage 'wearing-off' fluctuations by adding adjunctive therapies such as COMT inhibitors, MAO-B inhibitors, or Amantadine-IR 200 mg/day to reduce peak-dose dyskinesia.
- •Prescribe a cycling exercise protocol (40-60 minutes, 3 times per week) to improve movement vigor and significantly reduce the progression of urinary frequency.
- •Implement High-Intensity Expiratory Muscle Strength Training (EMST) at 60% of maximal expiratory pressure to improve swallowing safety and prevent .
- •Refer for bilateral subthalamic nucleus (STN) (DBS) in patients with advanced PD who experience medication-refractory motor fluctuations but remain levodopa-responsive.
- •Utilize non-invasive neuromodulation such as transcutaneous auricular vagus nerve stimulation (taVNS) to improve gait parameters and sleep quality.
- •Treat mild-to-moderate depressive symptoms with High-Definition Transcranial Direct Current Stimulation (HD-tDCS) targeting the left dorsolateral prefrontal cortex.
- •Address postural deformities like camptocormia using wearable sensor-based braces that provide vibratory feedback when forward flexion exceeds a pre-set threshold.
- •Manage chronic constipation using the '6S' model, emphasizing high fiber intake and standardized laxative protocols.
- •Screen for and manage bone health by performing a baseline DXA scan at diagnosis and initiating Vitamin D and Calcium supplementation to prevent fragility fractures.
- •Avoid typical antipsychotics (e.g., Haloperidol) and certain antiemetics (e.g., Metoclopramide) as they can severely exacerbate parkinsonian motor symptoms.
- •Consider Donor (dFMT) in drug-naïve patients to improve both motor and gastrointestinal symptoms via the gut-brain axis.
- •Transition to Continuous Subcutaneous Apomorphine Infusion (CSAI) in advanced stages if the oral route is compromised by severe or terminal illness.
- •Provide genetic counseling for patients with GBA1 or LRRK2 variants, focusing on variable penetrance and the implications for family members.
Board Review — High Yield
- •Lewy Bodies — Pathognomonic intracellular aggregates of misfolded alpha-synuclein.
- •Bradykinesia — The essential clinical feature required for diagnosis; characterized by slowness and decrement in amplitude.
- •RBD (REM Sleep Behavior Disorder) — A highly specific prodromal marker for future synucleinopathy development.
- •GBA1 Mutation — The most common genetic risk factor for Parkinson disease.
- •Micrographia — A classic clinical sign where handwriting becomes progressively smaller and cramped.
- •Pill-rolling tremor — A 4–6 Hz resting tremor that typically disappears with purposeful movement.
- •Honeymoon Period — The initial years of treatment where patients have a robust and stable response to levodopa.
- •Freezing of Gait — An episodic 'glued to the floor' sensation, often triggered by doorways or turning.
Deep Dive — Evidence Details
Definition, Synonyms, and Classification
- ▸Parkinson disease is increasingly defined by the biological presence of α-synuclein aggregates (detected via αSyn-SAA) rather than just clinical motor symptoms [14, 17].
- ▸The SynNeurGe framework (Synuclein, Neurodegeneration, Genetics) provides a multidimensional biological classification for research and future clinical practice [14].
Parkinson disease (PD) is a progressive neurodegenerative disorder characterized by the accumulation of misfolded α-synuclein aggregates and the selective loss of dopaminergic neurons in the substantia nigra pars compacta, leading to a constellation of motor and non-motor symptoms [2][17]D[20]D. Historically defined by its clinical motor features, the understanding of PD is currently in transition toward a biological framework that emphasizes molecular mechanisms over phenomenology [14]D[20]D. ### Synonyms and Alternate Names Also Called: Idiopathic Parkinson's Disease (IPD), Paralysis Agitans, Shaking Palsy, Primary [6][7][20]D.
Epidemiology and Risk Factors
- ▸The global prevalence of Parkinson disease is projected to reach 20 million by 2050, with age remaining the most significant risk factor.
- ▸Environmental factors such as dairy consumption and H. pylori infection increase risk, while residential greenness and potentially GLP-1 receptor agonists show protective associations.
Parkinson disease (PD) is a progressive neurodegenerative disorder and represents one of the fastest-growing causes of neurological disability worldwide [51]D. The global prevalence is increasing steadily, with projections suggesting that approximately 20 million individuals will be affected by 2050 [52]D. While traditionally viewed through the lens of motor dysfunction, PD is now recognized as a multisystem disorder where non-motor features often precede motor onset by decades, defining a critical prodromal phase [51]D.
Diagnosis and Workup
- ▸Diagnosis is primarily clinical, requiring bradykinesia plus tremor or rigidity, but clinical accuracy alone is often <93%.
- ▸Detection of phospho-α-synuclein in skin biopsies at C7/Th12 is a highly specific marker for differentiating PD from tauopathies like PSP.
The diagnosis of Parkinson Disease (PD) remains primarily clinical, though the integration of multimodal biomarkers and advanced imaging has significantly improved diagnostic accuracy and the ability to differentiate PD from other synucleinopathies and tauopathies [76]D[81]D. While the Unified Parkinson's Disease Rating Scale (UPDRS) is the gold standard for clinical assessment, its accuracy is often <93% due to subjective judgment and the clinical overlap between PD, Multiple System Atrophy (MSA), and (PSP) [76]D[71]D. ### Diagnostic Criteria
Clinical diagnosis is based on the identification of motor features and the exclusion of secondary causes.
Diagnosis and Differential Diagnosis
- ▸The detection of phospho-α-synuclein in skin biopsies is a critical tool for differentiating synucleinopathies (PD, MSA) from tauopathies (PSP).
- ▸31P MR spectroscopy provides a metabolic signature of midbrain energy homeostasis that can discriminate early-stage PD from its mimics.
The diagnosis of Parkinson Disease (PD) remains primarily clinical, centered on the identification of motor features resulting from the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta [98]D[99]D. However, the insidious onset and clinical overlap with other neurodegenerative disorders—specifically 'Parkinson-plus' syndromes—necessitate a rigorous diagnostic workup to differentiate idiopathic PD from mimics such as Multiple System Atrophy (MSA), (PSP), and Vascular (VP) [36][71]D. Recent advancements in molecular biomarkers, such as skin biopsies for phospho-α-synuclein and advanced phosphorus MR spectroscopy, have significantly enhanced diagnostic precision [71]D[74]D.
Management of Parkinson Disease
- ▸Levodopa timing is critical; even brief delays in administration in acute settings like the ED can lead to severe morbidity [28].
- ▸Symmetric Parkinson's disease is a predictor of poorer outcomes for both dopaminergic medication and subthalamic deep brain stimulation [122].
The of Parkinson Disease (PD) requires a multi-modal approach that integrates pharmacological optimization, surgical intervention, and targeted rehabilitation to address both motor and non-motor symptoms (NMS) [124]D. Because PD is a progressive neurodegenerative disorder, treatment must be dynamic, transitioning from symptomatic relief in early stages to complex management of motor fluctuations and cognitive changes in advanced disease [95]D[124]D. ### Step 1: Initial Assessment and Severity Classification Clinicians must first classify the disease phenotype and severity to determine the appropriate intervention path.
Supportive Care and Complication Management
- ▸Physical therapy efficacy is enhanced by cortical priming with intermittent theta-burst stimulation (iTBS).
- ▸Virtual reality (VR) and body weight-supported treadmill training (BWSTT) are superior for gait and balance rehabilitation.
- ▸Transcutaneous auricular vagus nerve stimulation (taVNS) improves both motor scores and non-motor symptoms like sleep.
- ▸Cycling for 40-60 minutes three times weekly may specifically slow the progression of urinary frequency in early PD.
- ▸Expiratory muscle strength training (EMST) is vital for preventing aspiration pneumonia, with mHealth apps improving long-term adherence.
- ▸Palliative care significantly improves quality of life, especially in underserved demographics.
Multidisciplinary Rehabilitation and Physical Therapy
Supportive care in Parkinson's disease (PD) has evolved from a limited evidence base to a robust field with over 240 randomized controlled trials as of 2026 [197]. Physical therapy (PT) remains a cornerstone of management, particularly for addressing the 'capacity-performance gap' in mobility and balance [197]. Recent evidence suggests that the efficacy of PT can be significantly enhanced through cortical priming; specifically, bilateral intermittent theta-burst stimulation (iTBS) over the primary motor cortex (M1) twice daily for two weeks has been shown to provide additional gains in motor function when combined with standard PT [199].
Gait and Balance Interventions
Gait impairments, including freezing of gait (FOG), often persist despite optimal pharmacological management [198]C. Modern interventions increasingly utilize technology to address these challenges:
- Virtual Reality (VR) and Treadmill Training: Systematic reviews indicate that VR protocols (typically 5 to 12 weeks) improve balance, gait speed, and dual-task performance [195]. Combining treadmill training with gamified virtual reality environments (GVRE) and transcranial direct current stimulation (tDCS) may further address motor-cognitive deficits that worsen under cognitive load [198]C. Non-immersive VR (NIVR) using semi-spherical devices has also demonstrated efficacy in improving UPDRS Part III scores and spatiotemporal gait parameters over 12 weeks [200].
- Body Weight-Supported Treadmill Training (BWSTT): This modality remains a high-quality option for mild-to-moderate PD, showing significant improvements in gait rehabilitation [195].
- Voluntary Walking and Specialized Mats: Structured voluntary walking interventions (>3 weeks or >6 sessions) significantly improve velocity, distance, and cadence [196]. Novel tools like the Fisior® sequential square mat, used in a 12-week progressive balance and resistance program, have shown efficacy in improving gait speed and physical performance [203].
- Rebound Therapy: Task-oriented exercises performed on a trampoline (rebound therapy) twice weekly for 6 weeks have proven more effective than stable-surface exercises for improving balance, gait, and knee strength [130].
Neuromodulation for Motor and Non-Motor Symptoms
Non-invasive neuromodulation is emerging as a versatile supportive therapy:
- Transcutaneous Auricular Vagus Nerve Stimulation (taVNS): Meta-analyses and clinical trials confirm that taVNS improves motor function (MDS-UPDRS III), gait parameters, and non-motor symptoms such as sleep and quality of life [111][131]. Neuroimaging suggests taVNS works by decreasing glutamate levels in the striatum and thalamus and enhancing brain connectivity [131].
- Transcranial Direct Current Stimulation (tDCS): When combined with standardized rehabilitation for FOG, anodal tDCS over the pre-motor/motor cortex can enhance the learning of cognitive and sensory cueing strategies, which are often difficult for patients to master due to cognitive load [127].
Exercise Modalities and Doses
Network meta-analyses of 44 RCTs involving 2,273 patients suggest that exercise modality and dose are critical for quality of life (QOL) [140].
- Cycling: In early PD, cycling exercise (three 40-60 minute sessions per week for 24 weeks) has been shown to selectively benefit autonomic symptoms, specifically reducing the progression of urinary frequency [112].
- Exergaming: Universally designed exergame programs are feasible and potentially effective even for patients in advanced stages (Hoehn & Yahr III-V) [128].
- Reactive Training: Home-based, time-constrained reactive training (e.g., visually guided reaching and stepping) can enhance movement speed and reduce reaction times in both upper and lower limbs [129].
Management of Pain and Respiratory Complications
- Pain Management: Chronic pain is a debilitating non-motor symptom. Combining Transcutaneous Electrical Nerve Stimulation (TENS) with a 20-minute exercise program has been investigated for its effects on pain intensity and fatigue [204]. For chronic shoulder pain (subacromial pain syndrome) in PD, ultrasound-guided suprascapular nerve block combined with pulsed radiofrequency (PRF) is effective, with outcomes potentially influenced by the severity of rigidity [205].
- Respiratory Care: Aspiration pneumonia is a leading cause of mortality in PD [63]. Expiratory muscle strength training (EMST) is recommended to improve swallowing and respiratory function. Adherence to long-term EMST can be significantly improved through mHealth interventions, such as the SpiroGym app [63].
Palliative Care and Telerehabilitation
Palliative care interventions have demonstrated significant benefits in improving QOL, particularly for underserved populations (rural, low-income, or minority groups) [201]. To increase accessibility, telerehabilitation (TR) via real-time videoconferencing has been shown to be a feasible method for delivering individualized physiotherapy in early-stage PD, potentially lowering costs and maximizing clinician reach [202]C.
| Intervention | Primary Benefit | Evidence Level |
|---|---|---|
| taVNS | Motor function, gait, and sleep | 1a [111], 1b [131] |
| VR Training | Balance and dual-task performance | 1a [195], 1b [200] |
| iTBS + PT | Enhanced motor function gains | 1b [199] |
| tDCS + Rehab | Improved learning of FOG strategies | 1b [127] |
| mHealth EMST | Respiratory/swallowing adherence | 2b [63] |
Special Populations in Parkinson Disease
- ▸Early-Onset Parkinson Disease (onset 21–50 years) requires a management strategy that prioritizes the delay of motor fluctuations and dyskinesias, which occur more frequently than in late-onset cases.
- ▸Elderly patients with PD have a nearly threefold increased risk of upper-thoracic vertebral fractures, necessitating early bone density screening and aggressive osteoporosis management.
Parkinson disease (PD) exhibits significant clinical heterogeneity, necessitating tailored strategies for specific patient subgroups. While the classic presentation involves older adults, the rising global burden of (EOPD) and the unique complications faced by the very elderly, pregnant patients, and those with specific comorbidities require distinct clinical approaches [46]D[154]D. ### Early-Onset Parkinson Disease (EOPD) EOPD is defined by a symptom onset between the ages of 21 and 50 years [154]D[46]D.
Guidelines and Resources
- ▸Balance dysfunction research requires a multimodal approach including video-oculography and posturography [206].
- ▸Hospitalized PD patients are at high risk due to medication timing errors and unrecognized dysphagia [181, 187].
- ▸Physical therapy is recommended as a mandatory complement to STN-DBS for axial symptoms [179].
- ▸Cerebral small vessel disease burden is significantly higher in PD patients compared to healthy controls and correlates with gait impairment [90].
- ▸GBA1 variant testing requires specialized genetic counseling to communicate the associated risk of PD [170].
- ▸Continuous subcutaneous apomorphine infusion (CSAI) initiation should be tailored to one of five specific patient profiles [207].
Clinical Practice Guidelines and Consensus Roadmaps
Recent international consensus efforts have focused on standardizing the management of Parkinson's disease (PD) across diverse clinical domains. A 2026 consensus roadmap addresses balance dysfunction, emphasizing that postural stability depends on multisensory integration and accurate perception of self-motion [206]. The roadmap advocates for standardized use of video-oculography, vestibular evoked myogenic potentials (VEMPs), and posturography to improve clinical translation [206]. For cognitive disorders, updated best practice guidelines established through a modified Delphi process provide 51 recommendations for the diagnosis and evaluation of cognitive impairment, incorporating both expert and lived-experience perspectives [168].
Management of Non-Motor and Hospitalized Symptoms
Non-motor symptoms significantly impact quality of life and disease progression [169]. The German Society of Neurology's 2025 guidelines provide evidence-based recommendations for managing autonomic failure, pain, and sleep disturbances [169]. Similarly, the Brazilian Academy of Neurology has released comprehensive recommendations for neuropsychiatric symptoms, including depression, anxiety, and psychosis [175].
In the hospital setting, specific risks such as medication timing errors, contraindicated medications, restricted mobility, and dysphagia must be addressed [181]. Expert recommendations for managing dysphagia in hospitalized patients emphasize that swallowing difficulties may be present without overt clinical signs, necessitating interdisciplinary collaboration between neurology, nursing, and speech-language pathology to prevent delays in medication administration [187]D. Furthermore, a systematic review of bone health guidelines highlights that PD patients face a high fracture risk due to low bone mineral density and frequent falls, requiring proactive osteoporosis management [174].
Advanced Therapies and Specialized Care Models
For patients with motor fluctuations, continuous subcutaneous apomorphine infusion (CSAI) is a key intervention. French practical guidelines now define five distinct patient profiles to guide the target dose and subsequent adjustment of oral treatments [207]. However, access to such device-aided therapies remains inconsistent; for instance, experts in Poland have identified significant gaps in the reimbursement of apomorphine and intestinal gel infusions [210].
Specialized care models, such as the Parkinson’s day-clinic, have been introduced to bridge the gap between ambulatory and inpatient care for advanced PD [208]. For patients treated with subthalamic deep brain stimulation (STN-DBS), a Delphi consensus study strongly recommends physical therapy to address dopamine-resistant symptoms like postural instability and freezing of gait [179]. Additionally, the use of safinamide for motor fluctuations has been standardized through regional expert consensus to optimize its clinical application [209].
Diagnostic Biomarkers and Emerging Technologies
Diagnostic accuracy is being refined through the study of cerebrospinal fluid (CSF) biomarkers and neuroimaging. Network meta-analyses suggest that CSF biomarkers can help differentiate PD from atypical parkinsonian syndromes, though their role as first-line tools is still being established [177]. Neuroimaging research indicates that PD patients exhibit a greater burden of cerebral small vessel disease (CSVD)—including white matter hyperintensities and microbleeds—which correlates with worse motor and gait scores [90]. Meta-analyses of resting-state fMRI have also identified altered regional spontaneous brain activity in PD [176].
To improve the reliability of clinical assessments, computer vision-based automated systems are being developed to correct rater discrepancies in MDS-UPDRS Part III scoring [211]. Furthermore, clinical consensus has been sought to define the meaningful motor progression threshold on the MDS-UPDRS Part III in the OFF medication state to better track disease evolution [212].
Travel, Genetics, and Palliative Care
Specific guidance has been developed for long-distance air travel, which may temporarily worsen motor and non-motor states due to dehydration, hypoxia, and jet lag [191]D. In genetics, consensus guidance for GBA1 variants—the most common genetic risk factor for PD—emphasizes the importance of standardized counseling regarding PD risk [170]. Finally, there is an increasing shift toward early palliative care, with research identifying indicators for timely access and the need to overcome organizational barriers to provide holistic support for patients and caregivers [178].
| Domain | Key Recommendation | Reference |
|---|---|---|
| Cognition | 51 evidence-based recommendations for diagnosis and management | [168] |
| Hospital Care | Avoid contraindicated medications and prioritize medication timing | [181] |
| Bone Health | Systematic screening for osteoporosis due to high fracture risk | [174] |
| Air Travel | Personalized pre-travel planning to mitigate hypoxia and jet lag effects | [191]D |
| DBS | Integration of physical therapy to treat dopamine-resistant gait issues | [179] |
References
- [1]
Gregson CL, Armstrong DJ, Avgerinou C et al.. “The 2024 UK clinical guideline for the prevention and treatment of osteoporosis.” Archives of osteoporosis (2025). PMID: 40921943 ↗
L1cGUIDELINECited in: Definition, Synonyms, and Classification - [2]
Xavier D, Felizardo V, Ferreira B et al.. “Voice analysis in Parkinson's disease - a systematic literature review.” Artificial intelligence in medicine (2025). PMID: 40132400 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [3]
Bradley M, O'Loughlin S, Donlon E et al.. “Determining Falls Risk in People with Parkinson's Disease Using Wearable Sensors: A Systematic Review.” Sensors (Basel, Switzerland) (2025). PMID: 40648326 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [4]
Moss Lopes PR, Westphal Filho FL, Mendes Filho FSM et al.. “Prevalence of Supine Hypertension in Alpha-Synucleinopathies: A Systematic Review and Meta-Analysis.” Movement disorders clinical practice (2025). PMID: 40406920 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [5]
Pecoraro PM, Marsili L, Espay AJ et al.. “Computer Vision Technologies in Movement Disorders: A Systematic Review.” Movement disorders clinical practice (2025). PMID: 40326633 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [6]
Sharma P, Singh SM, Mehta S et al.. “High-definition transcranial direct current stimulation for depressive and other non-motor symptoms in Parkinson's disease: a randomised, sham-controlled, cross-over study.” East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan (2026). PMID: 41916935 ↗
L1bRCTCited in: Definition, Synonyms, and Classification, Diagnosis and Workup, Differential Diagnosis, Management - [7]
Cole-Hunter T, Antic S, Lim YH et al.. “Long-Term Exposure to Air Pollution and Incidence of Parkinson's Disease: A Danish Nationwide Administrative Cohort Study.” Movement disorders : official journal of the Movement Disorder Society (2026). PMID: 41772748 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [8]
Davydow DS, Okun MS, Pontone GM. “Potential Risk Factors for Psychosis in Parkinson's Disease: A Review of Cohort and Case-Control Studies.” Journal of geriatric psychiatry and neurology (2025). PMID: 39925085 ↗
L3bCASE_CONTROLCited in: Definition, Synonyms, and Classification - [9]
Gilat M, Nonnekes J, Factor SA et al.. “An updated definition of freezing of gait.” Nature reviews. Neurology (2026). PMID: 41513745 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification, Guidelines and Resources - [10]
Rigon L, Poplawska-Domaszewicz K, Metta V et al.. “The challenges with the identification of Parkinson's disease subtypes.” Expert review of neurotherapeutics (2026). PMID: 41474600 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [11]
Bougea A. “Staging and markers in Parkinson's disease and Lewy body disorders: narrative review.” Therapeutic advances in chronic disease (2025). PMID: 41146744 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [12]
Ma H, Zhu Y, Zhao X et al.. “Pyroptosis: inflammatory cell death mechanism and its pathological roles in neurological diseases and injuries.” Apoptosis : an international journal on programmed cell death (2025). PMID: 40813542 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [13]
Factor SA, Weinshenker D, McKay JL. “A possible pathway to freezing of gait in Parkinson's disease.” Journal of Parkinson's disease (2025). PMID: 39973500 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [14]
Höglinger GU, Lang AE. “SynNeurGe: The road ahead for a biological definition of Parkinson's disease.” Journal of Parkinson's disease (2025). PMID: 39973492 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [15]
Bendetowicz D, Planche V, Bezard E et al.. “Biological definitions of synucleinopathies should be anchored in clinical trajectories and encompass the complex biology of the disease.” Journal of Parkinson's disease (2025). PMID: 39973487 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [16]
Tinazzi M, Geroin C, Siciliano M et al.. “Pain and fatigue in Parkinson's disease: advances in diagnosis and management.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 39937423 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [17]
Soto C, Mollenhauer B, Hansson O et al.. “Toward a biological definition of neuronal and glial synucleinopathies.” Nature medicine (2025). PMID: 39885358 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [18]
Lesley R, Simpson J, Dale M et al.. “Predictors of Informal Caregiver Burden in Parkinson's Disease: A Systematic Review.” Western journal of nursing research (2025). PMID: 40138495 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [19]
Cataldo E, de Oliveira Aguiar AG, Silva LAS. “A Methodological Review of Voice Acoustic Parameters, with Emphasis on Vocal Tremor: Definitions, Computation, and Software Tools.” Journal of voice : official journal of the Voice Foundation (2026). PMID: 41951462 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [20]
Fan SP, Okuzumi A, Chen PS et al.. “Parkinson's disease in transition: Genetics, biomarkers, and emerging therapeutics.” Journal of the Formosan Medical Association = Taiwan yi zhi (2025). PMID: 41353001 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [21]
Calzetti S, Calzetti G. “The nosology of tardive parkinsonism.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 41130187 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [22]
Subramanian I, Ricciardi L, Schrag A et al.. “A Holistic Wellness Prescription for Parkinson's Disease: Evidence-Based Perspectives and Unmet Needs.” Movement disorders clinical practice (2026). PMID: 41084417 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [23]
Brenlla C, Lazaro-Hernandez C, Fernandez M et al.. “Biomarkers of neurodegenerative parkinsonisms: From current clinical to future biological definitions - literature review and our experience.” Neurologia i neurochirurgia polska (2025). PMID: 40207871 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [24]
Markiewicz M, Madetko-Alster N, Alster P. “Quality of life in patients with progressive supranuclear palsy: a review of literature and implications for practice.” Frontiers in neurology (2024). PMID: 39634776 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [25]
Stinson SE, Shadrin AA, Rahman Z et al.. “Distinct metabolic signatures of Alzheimer's and Parkinson's disease revealed through genetic overlap.” EBioMedicine (2026). PMID: 41966729 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [26]
Ekert JO, Patel V, Zhou X et al.. “Enhancing 7T MRI for deep brain stimulation with deep-learning based image reconstruction and dynamic parallel transmission.” NeuroImage. Clinical (2026). PMID: 41962172 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [27]
Dinter E, Margraff JL, Schniewind I et al.. “CSF alpha-Synuclein Seed Amplification Assay results in routine clinically collected samples.” Journal of Parkinson's disease (2026). PMID: 41944207 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [28]
Elder NM, Lash EM, Tomkins-Tinch C. “An Underrecognized Problem: Missed and Delayed Carbidopa-Levodopa Administration in Emergency Department Patients With Parkinson's Disease.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2026). PMID: 41910596 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Management, Special Populations - [29]
Barbosa RP, Bastos P, Béreau M et al.. “Is being asymmetric a bad thing? Insights from a longitudinal observational study on STN-DBS Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41887013 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [30]
Park D, Lee WR, Bang M et al.. “Impact of Postoperative Chronic Back Pain Syndrome on the Incidence of Psychiatric and Brain Disorders, and All-Cause Mortality.” Journal of pain research (2026). PMID: 41710284 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [31]
Liu R, Zhang S, Xiao Y et al.. “The Effects of Digital Health Interventions on Motor Symptoms, Nonmotor Symptoms, and Quality of Life in Patients With Parkinson Disease: Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Journal of medical Internet research (2026). PMID: 41818739 ↗
L1aSR_MA_RCTCited in: Epidemiology and Risk Factors - [32]
Hemeda S, Elmadani M, Merzah M et al.. “Impact of Alcohol Intake on Parkinson's Disease Risk and Progression: A Systematic Review and Dose-Response Meta-Analysis of Prospective Studies.” Movement disorders : official journal of the Movement Disorder Society (2026). PMID: 41578833 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [33]
Yang D, Nepal G, Ojha R et al.. “Association between dairy consumption and Parkinson's disease: A systematic review and meta-analysis.” Public health (2026). PMID: 41544344 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [34]
Bang CS, Hasanuzzaman M, Lee JJ et al.. “Association between Helicobacter pylori infection and Parkinson's disease: A systematic review and meta-analysis.” European journal of clinical investigation (2026). PMID: 41527373 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [35]
Barer Y, Ast T, Chodick G et al.. “Incretin-based therapy and Parkinson's disease risk among patients with type 2 diabetes: Retrospective cohort study and meta-analysis.” Parkinsonism & related disorders (2026). PMID: 41468681 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [36]
Chen X, Barclay NL, Pineda-Moncusí M et al.. “Secular trends of incidence and prevalence of Parkinsonism subtypes: a cohort study in the United Kingdom.” European journal of public health (2026). PMID: 41954920 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Differential Diagnosis, Special Populations - [37]
Bae Y, Song C, Kim S et al.. “Risk of somatoform and sleep-related disorders in Parkinson's disease: A nationwide matched cohort study.” Sleep medicine (2026). PMID: 41812492 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [38]
Kamo H, Remz M, Mehta TR et al.. “Five-year risk of cardiovascular events and falling in Parkinson's disease with orthostatic hypotension: A nationwide cohort study.” Parkinsonism & related disorders (2026). PMID: 41637898 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [39]
Davoodi L, Frouzanian M, Soleymani E et al.. “Investigating the prevalence of Toxoplasma gondii infection in Parkinson's disease patients and its association with disease severity: a case-control study.” BMC infectious diseases (2026). PMID: 41526839 ↗
L3bCASE_CONTROLCited in: Epidemiology and Risk Factors, Special Populations - [40]
Kang MS, Jung YT, Kim S et al.. “Upper-thoracic predominance and non-vertebral fracture burden in Parkinson's disease: A matched Case-Control study.” Parkinsonism & related disorders (2026). PMID: 41468680 ↗
L3bCASE_CONTROLCited in: Epidemiology and Risk Factors, Special Populations - [41]
Huang X, Cheng Q, Xie Y et al.. “Chinese patent medicine in the treatment of Parkinson's disease: A systematic review and network meta-analysis.” Complementary therapies in clinical practice (2026). PMID: 41505870 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [42]
Cheng B, Cheng S, Wei W et al.. “Residential green space, natural environment, domestic garden, and the risk of Parkinson's disease: A prospective cohort study.” Neurobiology of disease (2026). PMID: 41759830 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [43]
Gusmão NA, Mateus APM, Oliveira VB et al.. “Parkinson's disease and Porphyromonas gingivalis levels: a case-control study.” Journal of applied oral science : revista FOB (2026). PMID: 41880470 ↗
L3bCASE_CONTROLCited in: Epidemiology and Risk Factors - [44]
Gomes de Luna JR, Lima DP, Gomes VC et al.. “Sarcopenia, body composition, physical performance, and clinical features in Parkinson's disease: a cross-sectional comparative study.” Frontiers in endocrinology (2026). PMID: 41924518 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup - [45]
Zhou L, Guan M, Zhang B et al.. “Depression in Parkinson's disease: prevalence and impact on oculomotor features.” Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2026). PMID: 41895089 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [46]
Shen Q, Zheng F, Dong Y et al.. “Global, regional, and national burden of Early-onset Parkinson's disease: A comprehensive analysis and forecast, 1990-2021.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 41876889 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Special Populations - [47]
Jian X, Yu P, Zhang Y et al.. “Large-scale profiling of blood microbial signatures in patients with Parkinson's disease and its association with disease progression: a cross-sectional study.” EBioMedicine (2026). PMID: 41864063 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [48]
Step K, Ndong Sima CAA, Grant S et al.. “Polygenic risk scores and Parkinson's disease in South Africa advancing ancestry informed disease prediction.” PLoS genetics (2026). PMID: 41801886 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [49]
Ahn SH, Kim DH, Park J et al.. “Dynamic Smoking Patterns and Risk of Parkinson Disease and All-Cause Mortality: A Competing Risk Analysis Approach.” Neurology (2026). PMID: 41740083 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [50]
Tang X, Cui H, Cui H. “Orchestrating the Parkinson's disease microenvironment in 3D for pathogenesis study and therapeutic development.” Biofabrication (2026). PMID: 41719587 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [51]
Arias-Carrión O. “Parkinson's Disease: From Gene-Environment Risk to Precision Therapy.” Medical sciences (Basel, Switzerland) (2026). PMID: 41718119 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [52]
Onrubia-Márquez M, Garcia MM, Navas F et al.. “MSN Templated with L-Dopa Amide Derivatives Outperforms the Efficiency of Free-L-Dopa in Reducing Parkinson's Behavioral Dysfunction in Mice.” International journal of nanomedicine (2026). PMID: 41710371 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [53]
Li S, Chen S, Yu X et al.. “Scoping review of AI-driven wearable technologies for rehabilitation and functional assessment in Parkinson's disease: a protocol.” BMJ open (2026). PMID: 41692525 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [54]
Vakhshoori M, Bondariyan N, Jones J et al.. “The impact of cardiovascular disease on Parkinson's disease: Findings from the PPMI study.” Parkinsonism & related disorders (2026). PMID: 41643580 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [55]
Li G, Li G. “The impact of diabetes mellitus in prodromal Parkinson's disease.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 41639475 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [56]
Sun M, Wang X, Lu Z et al.. “GLP-1RAs versus metformin and Parkinson's risk in type 2 diabetes.” Diabetes, obesity & metabolism (2026). PMID: 41582696 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [57]
Di Luca DG, de Havenon A, Prabhune A et al.. “Temporal trends and risk factors of hospital readmission following deep brain stimulation for Parkinson disease.” Parkinsonism & related disorders (2026). PMID: 41579428 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [58]
Mammen JR, Reddy V, Lerner A et al.. “Three years later: tracking bothersome symptoms and impacts for people with early Parkinson's disease.” Journal of neurology (2026). PMID: 41563488 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [59]
Park CW, Choi Y, Sun Y et al.. “Visuospatial dysfunction indicates an increased risk of rapid dementia conversion in Parkinson's disease.” Alzheimer's & dementia : the journal of the Alzheimer's Association (2026). PMID: 41540811 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [60]
Chen W, Du M, Liu M et al.. “Co-occurrence patterns and related risk factors of dementia and Parkinson's disease among older adults across 204 countries and territories: a spatial correspondence and systematic analysis.” BMC medicine (2026). PMID: 41540403 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [61]
Wu J, Zang W, Fang M et al.. “Effects of Wearable Devices on Parkinson Disease: Systematic Review and Meta-Analysis of Randomized Controlled Trials Within the International Classification of Functioning, Disability, and Health Framework.” Journal of medical Internet research (2026). PMID: 41849761 ↗
L1aSR_MA_RCTCited in: Diagnosis and Workup - [62]
Alla D, Shah D, Ramsundar R et al.. “Efficacy and Safety of Deferiprone for Parkinson's Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” Clinical neuropharmacology (Unknown). PMID: 41790482 ↗
L1aSR_MA_RCTCited in: Diagnosis and Workup - [63]
Srp M, Hoskovcova M, Lagnerova R et al.. “Enhancing Adherence to Home-Based Expiratory Muscle Strength Training in Parkinson Disease: Randomized Controlled Trial of an mHealth Intervention.” Journal of medical Internet research (2026). PMID: 41812147 ↗
L1bRCTCited in: Diagnosis and Workup, Management, Supportive Care and Complication Management - [64]
Raza H, Nizam B, Padaniya A et al.. “Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists in Parkinson Disease: A Systematic Review and Meta-Analysis.” Brain and behavior (2026). PMID: 41880197 ↗
L2aSR_OBSCited in: Diagnosis and Workup - [65]
Mohammed I, Nankya Y, Hong UT et al.. “The role of N-acetylcysteine and glutathione in the management of Parkinson's disease: a systematic review of oxidative biomarkers and clinical outcomes.” Amino acids (2026). PMID: 41874704 ↗
L2aSR_OBSCited in: Diagnosis and Workup - [66]
Boffino CC, Holzhacker TY, Silva SMA et al.. “Effects of galvanic vestibular stimulation on motor control in patients with Parkinson's disease: study protocol.” Arquivos de neuro-psiquiatria (2026). PMID: 41759503 ↗
L2bTRIAL_NONRANDOMCited in: Diagnosis and Workup, Management - [67]
Brito SAF, Scianni AA, Silveira BMF et al.. “High-intensity respiratory muscle training improves maximal respiratory pressures, breathing endurance, dyspnoea and exercise capacity in people with Parkinson's disease: a randomised trial.” Journal of physiotherapy (2026). PMID: 41933952 ↗
L1bRCTCited in: Diagnosis and Workup, Differential Diagnosis, Management, Supportive Care and Complication Management - [68]
Coskun K, Turan GB. “The Effects of Color Therapy on Fatigue, Depression, and Quality of Life in Parkinson's Patients: A Randomized Controlled Trial.” Brain and behavior (2026). PMID: 41888497 ↗
L1bRCTCited in: Diagnosis and Workup, Management - [69]
Baggen RJ, Van Bladel A, Prins MR et al.. “Visual perturbation training to reduce visual dependency in Parkinson's disease: A randomized controlled trial.” PloS one (2026). PMID: 41770816 ↗
L1bRCTCited in: Diagnosis and Workup, Management - [70]
Huang H, Zhu R, Zheng Y et al.. “Effect evaluation of the positive emotion, engagement, relationships, meaning, and accomplishment (PERMA) positive psychological intervention model in patients with Parkinson's disease.” Neuropsychology (2026). PMID: 41770127 ↗
L1bRCTCited in: Diagnosis and Workup - [71]
Lonczewski S, Bader V, Ortmann L et al.. “A Novel 3D Semi-Automated Full Quantification Technique for Detection of Intraneural Phospho-α-Synuclein in Skin Biopsies.” European journal of neurology (2026). PMID: 41995607 ↗
L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis, Special Populations - [72]
Sowalsky KL, Okun MS, Terza M et al.. “Regular Metronome, Fractal Metronome, and Music for Parkinson Gait.” JAMA network open (2026). PMID: 41989783 ↗
L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis, Management - [73]
Kim YJ, Choi SI, Yang H et al.. “Insole-Derived Plantar Pressure Variability Reveals Dual-Task Gait Differences in Early-Stage Parkinson's Disease.” IEEE journal of translational engineering in health and medicine (2026). PMID: 41970941 ↗
L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis, Special Populations - [74]
Yu Q, Zhang Y, Huang P et al.. “Midbrain Energy Homeostasis Biomarker for Differential Diagnosis of Early-Stage Parkinson Disease: A 1H and 31P MRI Study.” Radiology (2026). PMID: 41944724 ↗
L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis - [75]
Zhu S, Yi W, Feng Y et al.. “Decomposed Transfer Entropy for EEG Brain Networks: Parkinson's Disease and Dopaminergic Modulation.” IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society (2026). PMID: 41941809 ↗
L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis - [76]
Akram SW, K C. “Enhancing Parkinson's Disease Staging: An Integrative Deep Learning Framework for Multimodal Feature Selection.” Journal of molecular neuroscience : MN (2026). PMID: 41910849 ↗
L5OTHERCited in: Diagnosis and Workup - [77]
Lin J, Lee PY, Tran KKN et al.. “Detailed Outer Retinal Assessment in Parkinson's Disease Using Directional OCT.” Investigative ophthalmology & visual science (2026). PMID: 41910525 ↗
L5OTHERCited in: Diagnosis and Workup - [78]
Noor MS, Jadapalli J, Walker HC et al.. “Localizing beta synchronous neurons in the STN using directional DBS recordings and patient-specific biophysical models.” Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2026). PMID: 41881902 ↗
L5OTHERCited in: Diagnosis and Workup, Management - [79]
Boebinger SE, Payne AM, Xiao J et al.. “Cortically Mediated Muscle Responses to Balance Perturbations Increase with Perturbation Magnitude in Older Adults with and without Parkinson's Disease.” eNeuro (2026). PMID: 41871956 ↗
L5OTHERCited in: Diagnosis and Workup - [80]
Li Z, Yang R, Cui X et al.. “Orthostatic blood pressure trajectories characterize heterogeneous disease progression in Parkinson's disease.” Journal of neurology (2026). PMID: 41870682 ↗
L5OTHERCited in: Diagnosis and Workup - [81]
Niemi KJ, Jaakkola E, Myller EM et al.. “Striatal Dopamine Transporter and Rest Tremor in Parkinson Disease: A Clinical Validation.” Neurology (2026). PMID: 41855450 ↗
L5OTHERCited in: Diagnosis and Workup - [82]
Wang Q, Lv M, Zhou X et al.. “Association of choroid plexus volume with MRI indices of DTI-derived parameters and perivascular spaces in patients with neurodegenerative diseases.” European journal of radiology (2026). PMID: 41849872 ↗
L5OTHERCited in: Diagnosis and Workup, Special Populations - [83]
Morcillo-Martínez L, Sanz-Mármol M, Romanos-Navarrete AI et al.. “Effects of a level-based immersive virtual reality physical therapy program on static and dynamic balance in Parkinson's disease: Protocol for a randomized controlled trial.” PloS one (2026). PMID: 41838745 ↗
L2bTRIAL_NONRANDOMCited in: Diagnosis and Workup, Management, Special Populations - [84]
Wei X, Tian Y, Lu Q et al.. “Dynamic Reconfiguration of Cognitive Networks and Recovery From Microlesion Effects in Parkinson's Disease: Insights From a Longitudinal fNIRS Study.” CNS neuroscience & therapeutics (2026). PMID: 41834033 ↗
L5OTHERCited in: Diagnosis and Workup, Management - [85]
Gravel P, Gallezot JD, Fontaine K et al.. “Variance reduction with synaptic density imaging in Parkinson's disease using direct-4D PET image reconstruction.” Physics in medicine and biology (2026). PMID: 41825140 ↗
L5OTHERCited in: Diagnosis and Workup - [86]
Mezzini A, Kumar S, Sharrad S et al.. “The Topographical, Sensory, and Temporal Characteristics of Pain in Parkinson's Disease: A Cross-Sectional Survey.” Pain practice : the official journal of World Institute of Pain (2026). PMID: 41814463 ↗
L5OTHERCited in: Diagnosis and Workup, Special Populations - [87]
Kassubek J, Höglinger GU, Zůza A et al.. “Hypothalamic atrophy in progressive supranuclear palsy, assessed by convolutional neural network-based automatic segmentation.” Journal of neurology (2026). PMID: 41811373 ↗
L5OTHERCited in: Diagnosis and Workup - [88]
Jiang H, Chen G, Ma J et al.. “Precise estimation of tissue microstructure with hybrid graph transformer.” Artificial intelligence in medicine (2026). PMID: 41806520 ↗
L5OTHERCited in: Diagnosis and Workup - [89]
Mîndreanu R, Chiș IC, Sevastre-Berghian A et al.. “N-Acetylcysteine in Neurological Disorders: A Systematic Review of Clinical and Translational Evidence Across Seven Disorders.” International journal of molecular sciences (2026). PMID: 41977262 ↗
L2aSR_OBSCited in: Differential Diagnosis - [90]
Del Papa DF, Herman J, Kunju AT et al.. “Neurovascular Unit Dysfunction and Cerebral Small Vessel Disease in Parkinson Disease: A Systematic Review and a Meta Analysis.” Neurology (2026). PMID: 41955557 ↗
L2aSR_OBSCited in: Differential Diagnosis, Guidelines and Resources - [91]
Hu S, Lei J, You HJ. “Exercise for Non-Motor Symptoms of Parkinson's Disease: An Evidence-Based Review of Clinical Trials, Dosing Considerations, and Mechanistic Insights.” Neural plasticity (2026). PMID: 41918452 ↗
L2bTRIAL_NONRANDOMCited in: Differential Diagnosis, Management, Supportive Care and Complication Management - [92]
de Ronde EM, Birnie E, Rijpma A et al.. “Individualised stimlation parameters in deep brain stimulation for Parkinson's disease based on disease phenotype and brain connectivity: protocol for a randomised feasibility study in a tertiary care centre (iDBS trial).” BMJ open (2026). PMID: 41974545 ↗
L2bTRIAL_NONRANDOMCited in: Differential Diagnosis, Management - [93]
Zhu Y, Zhao L, Li Y et al.. “Disruption of Synaptic Vesicle Trafficking in Alzheimer's and Parkinson's Disease: Mechanisms and Therapeutic Implication.” International journal of molecular sciences (2026). PMID: 41977275 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [94]
Musarò D, Greco M, Lanza M et al.. “Copper Dyshomeostasis Affects α-Synuclein Clearance Mechanisms in Parkinson's Disease: Insights from In Vitro Models and Translational Evidence.” International journal of molecular sciences (2026). PMID: 41977181 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [95]
Almeida V, Herz DM, Blech J et al.. “Cognitive trajectories in Parkinson's disease patients, a review on the impact of subthalamic deep brain stimulation (STN-DBS) and emerging adaptive strategies.” Translational psychiatry (2026). PMID: 41963290 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis, Management - [96]
Ramanan S, Johnson GVW. “A Bioinformatic Analysis of BAG Protein Interactors and Pathways in Alzheimer's and Parkinson's Disease.” Journal of molecular neuroscience : MN (2026). PMID: 41925793 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [97]
Yin X, Wang C, Lin W et al.. “Nanotherapeutic Interventions for Parkinson's Disease: Modulating Pathogenic Mechanisms and Overcoming Therapeutic Obstacles.” International journal of nanomedicine (2026). PMID: 41907367 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis, Management - [98]
Ozkaya KS, Browning KN. “The Brain-Gut Axis in Parkinson's Disease Pathology.” Comprehensive Physiology (2026). PMID: 41905903 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [99]
Aslan FS, Barut B, Ozturk S et al.. “Neurotransmitter Dysregulation in Parkinson's Disease: Pathophysiological Insights and Therapeutic Perspectives.” ACS chemical neuroscience (2026). PMID: 41904982 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [100]
Davis A, Casmedes IY, Burton MD. “Radical Revelations: The Interplay of Nitrosative Stress, the Endocannabinoid System, and Treatment of Age-Related Disorders.” International journal of molecular sciences (2026). PMID: 41898672 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [101]
Rojas Romero CJ, Guerrero Y. “Singing-Based Interventions for Treating Hypokinetic Dysarthria in Parkinson's Disease: A Systematic Review.” Journal of music therapy (2026). PMID: 41990042 ↗
L2aSR_OBSCited in: Differential Diagnosis, Management - [102]
Garanin AA, Aydumova OY, Rubanenko AO et al.. “[Speech signal acoustic analysis in the diagnosis of neurological and mental diseases: a systematic review and meta-analysis].” Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2026). PMID: 41984552 ↗
L2aSR_OBSCited in: Differential Diagnosis - [103]
Jin J, Jiang Y, Zhou Y et al.. “AI-Enabled Flexible Sensing Ecosystems for Parkinson's Disease: Advancing Digital Biomarkers and Closed-Loop Interventions.” Sensors (Basel, Switzerland) (2026). PMID: 41977856 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [104]
Singhal M, Grannie C, Burnette M et al.. “Freezing of Gait in Parkinson's Disease: A Scoping Review on the Path Towards Real-Time Therapies.” Sensors (Basel, Switzerland) (2026). PMID: 41977827 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [105]
Shi WQ, Zhuang JH, Zhang QH et al.. “Synthesis and Biological Evaluation of RBG Derivatives as Nrf2 Activators for the Treatment of Parkinson's Disease.” International journal of molecular sciences (2026). PMID: 41977502 ↗
L5OTHERCited in: Differential Diagnosis - [106]
Toledano-Pinedo M, Porro-Pérez A, Schäker-Hübner L et al.. “Polyfunctionalized N-Arylsulfonyl Indoles: Identification of (E)-N-Hydroxy-3-{3-[(5-(3-(piperidin-1-yl)propoxy]-1H-indol-1-yl)sulfonyl]phenyl}acrylamide (MTP150) for the Epigenetic-Based Therapy of Parkinson's Disease.” International journal of molecular sciences (2026). PMID: 41977320 ↗
L5OTHERCited in: Differential Diagnosis - [107]
Yang JC, Situ J, Troutman R et al.. “A microbiome quantitative trait locus in SLC39A8 modulates disease severity in synucleinopathy-induced models of Parkinson's disease.” Human molecular genetics (2026). PMID: 41955304 ↗
L5OTHERCited in: Differential Diagnosis - [108]
Yang D, Xu J, Zhu Y et al.. “The genetic associations of DNAJC family members with Parkinson's disease: comprehensive evidence from burden analysis and Mendelian randomization.” Human genetics (2026). PMID: 41951985 ↗
L5OTHERCited in: Differential Diagnosis - [109]
Gowied HG, El-Mezayen NS, Afify EA. “Valsartan promotes neuroprotection in Parkinson's disease via epigenetic modulation and activation of the ASCL1/Nurr1 pathway.” Life sciences (2026). PMID: 41936814 ↗
L5OTHERCited in: Differential Diagnosis - [110]
Ahumada-Montalva P, Muñoz-Carvajal F, Bórquez-Macaya S et al.. “TMBIM6 enhances dopaminergic neuron survival by modulating the IRE1a pathway in Parkinson's disease.” Cell death & disease (2026). PMID: 41932887 ↗
L5OTHERCited in: Differential Diagnosis - [111]
Liu C, Jin Y, Lin H et al.. “Effects of transcutaneous auricular vagus nerve stimulation on motor and gait performance in Parkinson's disease: a meta-analysis of randomized controlled trials.” Journal of neurology (2026). PMID: 41805933 ↗
L1aSR_MA_RCTCited in: Management, Supportive Care and Complication Management - [112]
Jun JS, Kang N, Park K et al.. “Cycling exercise for autonomic symptoms in early Parkinson's disease.” Autonomic neuroscience : basic & clinical (2026). PMID: 41740291 ↗
L1bRCTCited in: Management, Supportive Care and Complication Management - [113]
Fidan C. “Technologies used in Parkinson's disease: a meta-analysis of their effect on health-related quality of life.” Journal of neurology (2026). PMID: 41817821 ↗
L2aSR_OBSCited in: Management - [114]
Zhang X, Zheng L, Li Y et al.. “Efficacy of rTMS and TBS on the motor symptoms in Parkinson's disease: a network meta-analysis.” Journal of neurology (2026). PMID: 41817817 ↗
L2aSR_OBSCited in: Management - [115]
Senthilkumar S, S M, Rizvi MF et al.. “Deep brain stimulation beyond Motor control: A systematic review and meta-analysis of sleep outcomes in Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41702753 ↗
L2aSR_OBSCited in: Management - [116]
van der Linden C, Berger T, Dembek TA et al.. “Tractography-guided versus clinical contact selection for deep brain stimulation in tremor - A prospective clinical trial.” Brain stimulation (2026). PMID: 41740836 ↗
L2bTRIAL_NONRANDOMCited in: Management - [117]
Zhang R, Feng R, Wang J et al.. “Gut microbiota modulation via repeated donor fecal transplantation improves motor and gastrointestinal symptoms in drug-naïve Parkinson's disease: a randomized phase 2 trial.” Signal transduction and targeted therapy (2026). PMID: 41826284 ↗
L1bRCTCited in: Management - [118]
Ferrara PE, Della Casa E, Calciano R et al.. “Effects of Focal Muscle Vibration on Static and Dynamic Balance in Patients with Parkinson's Disease: Preliminary Results of a Retrospective Study.” Medicina (Kaunas, Lithuania) (2026). PMID: 41752699 ↗
L2bCOHORTCited in: Management - [119]
Hu W, Li Y, Yang A et al.. “Research progress on employing medicinal plants and their active compounds to target autophagic pathways for Parkinson's disease therapy.” Journal of ethnopharmacology (2026). PMID: 41895540 ↗
L2aSR_OBSCited in: Management - [120]
Pinheiro RSA, Silva Júnior HBD, Guimarães BB et al.. “Effects of Transcranial Direct Current Stimulation on Speech and Voice Changes in Parkinson's Disease: a Systematic Review with Meta-Analysis.” CoDAS (2026). PMID: 41779498 ↗
L2aSR_OBSCited in: Management - [121]
Busot D, Yang H, Sawmiller D et al.. “The Progress of Active Immunotherapy for Parkinson's Disease.” International journal of molecular sciences (2026). PMID: 41828418 ↗
L5REVIEW_NARRATIVECited in: Management - [122]
Jost ST, Atwani C, Loehrer PA et al.. “Patients with symmetric Parkinson's disease do poorly with subthalamic stimulation.” Journal of neurology, neurosurgery, and psychiatry (2026). PMID: 41781214 ↗
L5OTHERCited in: Management - [123]
Li J, Liu T, Wei J. “Exercise as Chronotherapy: Regulating Circadian Rhythms to Alleviate Symptoms in Parkinson's Disease.” ACS chemical neuroscience (2026). PMID: 41766127 ↗
L5REVIEW_NARRATIVECited in: Management - [124]
Rajyasree A, Balamurugan J. “"Every day is a battle against Parkinson's"-a qualitative study on older adults at the long-term care facilities in Chennai.” Frontiers in public health (2026). PMID: 41756082 ↗
L5OTHERCited in: Management, Special Populations - [125]
Qiu S, Wei Y, Gao C et al.. “Effects of combined transcranial direct current stimulation and gait training in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.” Systematic reviews (2025). PMID: 41053827 ↗
L1aSR_MA_RCTCited in: Supportive Care and Complication Management - [126]
Lima JL, Inacio PA, Sá Filho A et al.. “Effectiveness of virtual reality rehabilitation with exergames on functional rehabilitation in Parkinson's disease: a systematic review of chronic randomized controlled trials.” Expert review of neurotherapeutics (2025). PMID: 40963232 ↗
L1aSR_MA_RCTCited in: Supportive Care and Complication Management - [127]
Madrid J, Batzianouli E, Rutz D et al.. “Can transcranial Direct Current Stimulation enhance the efficacy of a rehabilitative intervention for the treatment of Freezing of Gait in Parkinson's disease? A double-blind, randomized controlled study.” Journal of Parkinson's disease (2026). PMID: 41637203 ↗
L1bRCTCited in: Supportive Care and Complication Management - [128]
Matsushita W, Nagaki K, Takashi N et al.. “Feasibility and potential effectiveness of an exergame program for people with moderate to advanced Parkinson's disease: A pilot randomized controlled trial.” Journal of Parkinson's disease (2026). PMID: 41637155 ↗
L1bRCTCited in: Supportive Care and Complication Management - [129]
Villamil-Cabello E, Molinero-Martín E, Luque-Casado A et al.. “Home-Based time-constrained reactive training enhances movement speed in upper and lower limbs in Parkinson's disease: A randomized controlled trial.” Journal of Parkinson's disease (2026). PMID: 41615860 ↗
L1bRCTCited in: Supportive Care and Complication Management - [130]
Eldemir S, Polat EA, Gokdogan CM et al.. “The effect of rebound therapy in Parkinson's disease: A single-blinded randomized controlled trial.” Gait & posture (2026). PMID: 41592453 ↗
L1bRCTCited in: Supportive Care and Complication Management, Special Populations - [131]
Wang R, Liu M, Liu Q et al.. “Home-based transcutaneous auricular vagus nerve stimulation (taVNS) improves motor and non-motor symptoms by improving autonomic and brain functions in patients with Parkinson's disease: A randomized clinical trial.” Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (2026). PMID: 41549029 ↗
L1bRCTCited in: Supportive Care and Complication Management - [132]
Kalva-Filho CA, Zampier VC, Orcioli-Silva D et al.. “Inter-effort recovery hypoxia did not mitigate acute treadmill effects in people with Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41389475 ↗
L1bRCTCited in: Supportive Care and Complication Management - [133]
Rascol O, Ory-Magne F, Meissner WG et al.. “Effect on Dyskinesia of the Early Combination of Amantadine to Levodopa-Therapy in Parkinson's Disease: A Randomized, Placebo-Controlled Study (PREMANDYSK).” Movement disorders : official journal of the Movement Disorder Society (2026). PMID: 41316871 ↗
L1bRCTCited in: Supportive Care and Complication Management - [134]
da Conceição NR, Vitório R, Morya E et al.. “Effect of Dynamic Balance Training Combined with Different Intensities of Cerebellar Transcranial Direct Current Stimulation in People with Parkinson's Disease: a Randomized Clinical Trial.” Cerebellum (London, England) (2025). PMID: 41239034 ↗
L1bRCTCited in: Supportive Care and Complication Management - [135]
Topal A, Durmaz Çelik N, Ayık B et al.. “Effect of a Wearable Sensor-Based Posture Correction Brace on Static Balance and Posture in Parkinson's Disease.” American journal of physical medicine & rehabilitation (2026). PMID: 41082253 ↗
L1bRCTCited in: Supportive Care and Complication Management - [136]
Thanakamchokchai J, Ajjimaporn A, Richards J et al.. “High-frequency rTMS and home-based exercise in individuals with Parkinson's disease: A double-blind randomized controlled trial.” Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2025). PMID: 40934835 ↗
L1bRCTCited in: Supportive Care and Complication Management - [137]
Hernandez-Martinez J, Branco BHM, Cid-Calfucura I et al.. “Exergaming Compared to Conventional Physical Exercise Interventions on Health Status in Older People with Parkinson's Disease: A Systematic Review with Meta-Analysis of Randomized Controlled Trials.” Medicina (Kaunas, Lithuania) (2025). PMID: 41303837 ↗
L1aSR_MA_RCTCited in: Supportive Care and Complication Management - [138]
Mollinedo-Cardalda I, Monge-Pereira E, Pereira-Pedro KP et al.. “Acute effects of an aerobic dual task on processing speed and attention in Parkinson's disease: a randomised controlled trial study.” Journal of bodywork and movement therapies (2025). PMID: 41316559 ↗
L1bRCTCited in: Supportive Care and Complication Management - [139]
Li Y, Liu Y, Lin Z et al.. “Aerobic exercise modulates plasma oxidized lipid metabolites and neurotransmitters in Parkinson's disease motor subtypes.” Brain research (2025). PMID: 41205731 ↗
L1bRCTCited in: Supportive Care and Complication Management - [140]
Zeng B, Wang H, Chen J et al.. “Optimal exercise modalities and doses for improving quality of life in patients with Parkinson's disease: a network meta-analysis and dose-response study.” Journal of neurology (2026). PMID: 41656425 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [141]
Yan HL, Li MM. “Effects of exercise modalities on cognitive function and depression in patients with Parkinson's disease: A systematic review and network meta-analysis.” Geriatric nursing (New York, N.Y.) (2025). PMID: 41129905 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [142]
Han C, Zhang H, Wang Q et al.. “Physical exercise and inflammation in Parkinson's disease: a review.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 41085917 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [143]
Decaix T, Bonnin C, Götze K et al.. “Benefits of physical activity on cognitive function in patients with neurocognitive disorders: A systematic review.” The Journal of frailty & aging (2025). PMID: 40911419 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [144]
Xiao C, Zhou F. “Yi Jin Jing Exercise Program Improves in Cognition, Sleep and Functional Mobility for Mild and Moderate Parkinson 's Disease: A Randomized Controlled Trial.” Experimental aging research (2026). PMID: 41388828 ↗
L1bRCTCited in: Supportive Care and Complication Management - [145]
Fukuchi CA, Moreno VC, Kalva-Filho CA et al.. “Combining automated mechanical peripheral stimulation and treadmill exercise for gait rehabilitation in Parkinson's disease: A randomized controlled trial.” Clinical biomechanics (Bristol, Avon) (2026). PMID: 41337903 ↗
L1bRCTCited in: Supportive Care and Complication Management - [146]
González-García P, Heredia-Rizo AM, Garrido-Bueno A et al.. “Multi-Session whole body vibration program on Parkinson's disease symptoms: Systematic review and meta-analysis.” Journal of bodywork and movement therapies (2025). PMID: 41316661 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [147]
Domínguez-Pera I, Lucena-Anton D, Estebanez-Perez MJ et al.. “Efficacy of transcranial direct current stimulation combined with gait training in patients with Parkinson's disease: Systematic review and meta-analysis.” CNS spectrums (2025). PMID: 41065007 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [148]
Taveira RS, Vasconcellos LS, Bezerra CF et al.. “Telerehabilitation for people with Parkinson's disease: protocol of a randomised clinical trial of mixed methods.” BMJ open (2025). PMID: 41320221 ↗
L2bTRIAL_NONRANDOMCited in: Supportive Care and Complication Management - [149]
Tufft A, Neilens H, Marsden J et al.. “Efficacy of peroneal nerve functional electrical stimulation (FES) for the reduction of bradykinesia in Parkinson's disease: an assessor-blinded randomised controlled trial (STEPS II)-study protocol.” BMJ open (2025). PMID: 40912703 ↗
L2bTRIAL_NONRANDOMCited in: Supportive Care and Complication Management - [150]
Greenland JC, Dresser K, Cutting E et al.. “Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.” The Lancet. Neurology (2026). PMID: 41389828 ↗
L1bRCTCited in: Special Populations - [151]
Song T, Xiang L, Liu Y et al.. “Survival and related factors in patients with Parkinson's disease: a multicenter prospective cohort study in China.” Journal of neurology (2026). PMID: 41507598 ↗
L2bCOHORTCited in: Special Populations - [152]
Fleet JL, Carter B, Cadarette SM et al.. “Fracture incidence and osteoporosis treatment in Parkinson's disease: a population-based cohort study.” Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2026). PMID: 41369770 ↗
L2bCOHORTCited in: Special Populations - [153]
Erfmann K, Hirschwald J, Hofacker J et al.. “Characteristics of Swallowing Function in People with Parkinson's Disease: A Scoping Review.” Movement disorders : official journal of the Movement Disorder Society (2026). PMID: 41508417 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [154]
Hickman J, Tsai A, Fullard M et al.. “Early-Onset Parkinson's Disease: Unique Features and Management Approaches.” Current neurology and neuroscience reports (2025). PMID: 41410819 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [155]
Calzada García M, Ayala A, Navarta Sánchez MV et al.. “[Impact of a community-based multisectoral intervention on the health of individuals with parkinson's disease and their family caregivers].” Semergen (2026). PMID: 41707402 ↗
L1bRCTCited in: Special Populations - [156]
Machane D, Shaji MS, Borchman D et al.. “Meibum Lipid Saturation Related to Dry Eye, Age, and Sex Using Nuclear Magnetic Resonance Spectroscopy.” Investigative ophthalmology & visual science (2026). PMID: 41910524 ↗
L5OTHERCited in: Special Populations - [157]
Sriram D, Pourzinal D, Bailey DX et al.. “Recommendations to Improve Healthcare Service Provision for Cognitive Impairment in People With Parkinson's Disease: A Mixed Methods Study of the Lived Experience Expert Perspective.” Health expectations : an international journal of public participation in health care and health policy (2026). PMID: 41834361 ↗
L5OTHERCited in: Special Populations, Guidelines and Resources - [158]
Hatakeyama S, Miki Y, Tanaka MT et al.. “Cerebrospinal fluid HOMER1 and NPTX2 as candidate signatures in early-stage multiple system atrophy-parkinsonism.” Journal of the neurological sciences (2026). PMID: 41780424 ↗
L5OTHERCited in: Special Populations - [159]
Lian J, Fan Z, Petrazzini BO et al.. “Subtyping Alzheimer's disease and Parkinson's disease using longitudinal electronic health records.” Nature aging (2026). PMID: 41748957 ↗
L5OTHERCited in: Special Populations - [160]
Falk L, Brunius C, Crnic Bojkovic T et al.. “A data-driven SSM/PCA analysis approach for differential diagnosis of parkinsonism using 11C-PE2I PET.” NeuroImage. Clinical (2026). PMID: 41719754 ↗
L5OTHERCited in: Special Populations - [161]
Bolsewig K, Bellomo G, Hok-A-Hin YS et al.. “A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders.” Nature medicine (2026). PMID: 41699128 ↗
L5OTHERCited in: Special Populations - [162]
Anis S, Kundrick A, Callegari Piccinin C et al.. “Phosphorylated alpha-synuclein skin biopsy alters diagnosis in two out of three patients: Initial findings in a tertiary center.” Parkinsonism & related disorders (2026). PMID: 41691977 ↗
L5OTHERCited in: Special Populations - [163]
Ou C, Chen B, Yu H et al.. “Association between the triglyceride-glucose frailty index and Parkinson's disease in middle-aged and older adults: a comparative cross-national analysis of NHANES and CHARLS.” Parkinsonism & related disorders (2026). PMID: 41691976 ↗
L5OTHERCited in: Special Populations - [164]
Kim D, Tjaden K, Stipancic KL et al.. “Variable Speech Cueing Effects in Talkers With Parkinson's Disease.” American journal of speech-language pathology (2026). PMID: 41666082 ↗
L5OTHERCited in: Special Populations - [165]
Gunawardana CW, Burke PGR, Ignatavicius A et al.. “Comparing phenotypic features between Parkinson's disease dementia and dementia with Lewy bodies.” Journal of neurology (2026). PMID: 41665721 ↗
L5OTHERCited in: Special Populations - [166]
Singovski S, Harlé L, Zerbit J et al.. “Continuous subcutaneous apomorphine infusion to improve comfort in advanced degenerative Parkinsonian syndrome patients: a retrospective descriptive study in a home-based setting.” Parkinsonism & related disorders (2026). PMID: 41653908 ↗
L5OTHERCited in: Special Populations - [167]
Hobson R, Levy SHS, Singal CMS et al.. “Clonal CD8+ T cells populate the leptomeninges and coordinate with immune cells in human degenerative brain diseases.” Nature immunology (2026). PMID: 41593242 ↗
L5OTHERCited in: Special Populations - [168]
Pourzinal D, Brooks D, Sriram D et al.. “Best practice guidelines for the diagnosis, evaluation, and management of cognitive disorders in Parkinson's disease.” Age and ageing (2026). PMID: 41870152 ↗
L1cGUIDELINECited in: Guidelines and Resources - [169]
Fanciulli A, Sixel-Döring F, Buhmann C et al.. “Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson's disease: guideline "Parkinson's disease" of the German Society of Neurology.” Journal of neurology (2025). PMID: 39751950 ↗
L1cGUIDELINECited in: Guidelines and Resources - [170]
Vieira SRL, Mezabrovschi R, Toffoli M et al.. “Consensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease.” Movement disorders : official journal of the Movement Disorder Society (2024). PMID: 39258449 ↗
L1cGUIDELINECited in: Guidelines and Resources - [171]
Witt K, Levin J, van Eimeren T et al.. “Diagnostics and treatment of impulse control disorders, psychosis and delirium: systemic review-based recommendations - guideline "Parkinson's disease" of the German Society of Neurology.” Journal of neurology (2024). PMID: 39046524 ↗
L1cGUIDELINECited in: Guidelines and Resources - [172]
Tönges L, Buhmann C, Eggers C et al.. “Guideline "Parkinson's disease" of the German Society of Neurology (Deutsche Gesellschaft für Neurologie): concepts of care.” Journal of neurology (2024). PMID: 38969876 ↗
L1cGUIDELINECited in: Guidelines and Resources - [173]
Walter U, Loewenbrück KF, Dodel R et al.. “Systematic review-based guideline "Parkinson's disease" of the German Society of Neurology: diagnostic use of transcranial sonography.” Journal of neurology (2024). PMID: 38963440 ↗
L1cGUIDELINECited in: Guidelines and Resources - [174]
Ó Breasail M, Singh KP, Lithander FE et al.. “Management of Osteoporosis in Parkinson's Disease: A Systematic Review of Clinical Practice Guidelines.” Movement disorders clinical practice (2025). PMID: 39704021 ↗
L1cGUIDELINECited in: Guidelines and Resources - [175]
Maia DP, Cury RG, Brandão PRP et al.. “Guidelines for Parkinson's disease management part II: consensus from the movement disorders scientific department of the Brazilian Academy of Neurology - non-motor symptoms.” Arquivos de neuro-psiquiatria (2025). PMID: 39993447 ↗
L1cGUIDELINECited in: Guidelines and Resources - [176]
Liao J, Wang L, Liu R et al.. “Altered regional spontaneous brain activity in Parkinson's disease: a meta-analysis.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 41579202 ↗
L2aSR_OBSCited in: Guidelines and Resources - [177]
Li S, Yang C, Wu J et al.. “Cerebrospinal fluid biomarkers for diagnosis of Parkinson's disease: a systematic review and network meta-analysis.” Journal of neurology (2025). PMID: 41324773 ↗
L2aSR_OBSCited in: Guidelines and Resources - [178]
Garon M, Weck C, Leta V et al.. “Early thinking palliative care for people with Parkinson's disease: A thematic synthesis based on a systematic mixed-methods review.” Journal of Parkinson's disease (2025). PMID: 40320755 ↗
L2aSR_OBSCited in: Guidelines and Resources - [179]
Guidetti M, Marceglia S, Bocci T et al.. “Is physical therapy recommended for people with parkinson's disease treated with subthalamic deep brain stimulation? a delphi consensus study.” Journal of neuroengineering and rehabilitation (2025). PMID: 40211348 ↗
L2aSR_OBSCited in: Guidelines and Resources - [180]
Rosado-Martins F, Santos B, Costa CM et al.. “Vestibular Dysfunction in Parkinson's Disease: A Systematic Review of Signs and Symptoms.” Movement disorders clinical practice (2026). PMID: 40854008 ↗
L2aSR_OBSCited in: Guidelines and Resources - [181]
Veilleux Carpentier A, Malaty IA, LeWitt PA et al.. “A Systematic Review of the Parkinson's Foundation Hospital Care Recommendations.” Movement disorders clinical practice (2026). PMID: 40736219 ↗
L2aSR_OBSCited in: Guidelines and Resources - [182]
Lima DP, Gomes VC, Luna JRG et al.. “Assessment of sarcopenia tools as predictors of falls in patients with mild to moderate Parkinson's Disease: A cohort study.” Clinics (Sao Paulo, Brazil) (2025). PMID: 40972508 ↗
L2bCOHORTCited in: Guidelines and Resources - [183]
Cordillet S, Drapier S, Leh F et al.. “Detecting Freezing of Gait in Parkinson Disease Using Multiple Wearable Sensors Sets During Various Walking Tasks Relative to Medication Conditions (DetectFoG): Protocol for a Prospective Cohort Study.” JMIR research protocols (2025). PMID: 39913915 ↗
L2bTRIAL_NONRANDOMCited in: Guidelines and Resources - [184]
Gülke E, Lewis SJG. “What is new in Freezing of Gait?” Journal of neurology (2026). PMID: 41865085 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources - [185]
Chen K, Hao W, Ji Y et al.. “Two novel iron metabolism-related genes identified as diagnostic indicators in substantia nigra of patients with Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41643581 ↗
L5OTHERCited in: Guidelines and Resources - [186]
Anis S, Clark PA, Shaffer S et al.. “Introducing a workflow algorithm for adaptive DBS programming in Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41577516 ↗
L5OTHERCited in: Guidelines and Resources - [187]
Safarpour D, Brooks A, Smiley A et al.. “Consensus expert recommendations for management of dysphagia during hospital admission in Parkinson's disease.” Journal of Parkinson's disease (2026). PMID: 41490026 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources - [188]
Pedrosa AJ, Molter JN, Brito de Almeida L et al.. “A modified Delphi study of post-operative management for subthalamic deep brain stimulation in Parkinson's disease.” Journal of Parkinson's disease (2026). PMID: 41217788 ↗
L5OTHERCited in: Guidelines and Resources - [189]
Rosenbohm A, Nguyen-Younossi N, Kassubek J. “Parkinson's disease-associated camptocormia: biopsy-confirmed focal myositis and treatment options.” Journal of neurology (2025). PMID: 41131373 ↗
L5OTHERCited in: Guidelines and Resources - [190]
Houston E, Boyd S, Iyer V et al.. “The need for developing consensus-based guidelines in assessing Parkinson's disease laterality.” Parkinsonism & related disorders (2025). PMID: 41039696 ↗
L5OTHERCited in: Guidelines and Resources - [191]
Poplawska-Domaszewicz K, Kaasinen V, van der Plas AA et al.. “Management of neuropsychiatric, motor and non-motor symptoms in Parkinson´s disease after long distance air travel: a consensus view.” Journal of neural transmission (Vienna, Austria : 1996) (2025). PMID: 40986033 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources - [192]
Sajin V, Goodall M, Macerollo A. “Camptocormia in Parkinson's disease: state of the art and future directions.” Journal of neurology (2025). PMID: 40975851 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources - [193]
Wang S, Zhou F, Fang X et al.. “Evidence-based summary of the prevention and management of constipation in patients with Parkinson's disease.” Geriatric nursing (New York, N.Y.) (2025). PMID: 40834448 ↗
L5OTHERCited in: Guidelines and Resources - [194]
Middlebrooks EH, Bot M, Patriat R et al.. “Multi-institutional recommendations on the use of 7T MRI in deep brain stimulation.” Journal of neurosurgery (2025). PMID: 40614283 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources - [195]
Battaglion GGS, Boni FDS, Zhang K et al.. “Virtual Reality and Body Weight-Supported Treadmill Training in Gait Rehabilitation for Parkinson Disease: A Systematic Review.” American journal of physical medicine & rehabilitation (2026). PMID: 41811930 ↗
L1aCited in: Supportive Care and Complication Management - [196]
Kloster CT, Bonde-Jensen F, Langeskov-Christensen M et al.. “Parkinson's Disease and Voluntary Walking Interventions-A Systematic Review and Meta-analysis.” Archives of physical medicine and rehabilitation (2026). PMID: 41628826 ↗
L1aCited in: Supportive Care and Complication Management - [197]
Ellis T. “Movement Through Time: The Evolution of Treatment for People With Parkinson Disease.” Journal of neurologic physical therapy : JNPT (2026). PMID: 42313921 ↗
L1bCited in: Supportive Care and Complication Management - [198]
Bosch-Barceló P, Tersa-Miralles C, Martínez-Navarro O et al.. “A treadmill training program in a gamified virtual reality environment combined with transcranial direct current stimulation in Parkinson's Disease: Preliminary results of a mixed methods randomized controlled trial.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 42277373 ↗
L4Cited in: Supportive Care and Complication Management - [199]
Zhang HY, Hou TT, Chen KK et al.. “Intermittent theta-burst stimulation to enhance physical therapy in Parkinson's disease: The STEP-PD randomized trial.” Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (2026). PMID: 41926908 ↗
L1bCited in: Supportive Care and Complication Management - [200]
Lim S, Park J, Kim J et al.. “Clinical efficacy of a non-immersive virtual reality-based balance training device in improving balance and gait in Parkinson's disease; A randomized controlled trial.” Parkinsonism & related disorders (2026). PMID: 41855753 ↗
L1bCited in: Supportive Care and Complication Management - [201]
Yilmaz S, Aslam S, Sillau S et al.. “Bridging the gap: Evaluating a community-based palliative care intervention for underserved patients with Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41812391 ↗
L1bCited in: Supportive Care and Complication Management - [202]
Skelly R, Lindop F, Gordon AL et al.. “Telerehabilitation for early-stage Parkinson's disease: A randomized controlled feasibility trial of individualised real-time physiotherapy delivered via a videoconference platform.” Journal of Parkinson's disease (2026). PMID: 41719152 ↗
L4Cited in: Supportive Care and Complication Management - [203]
Alegre-Tamariz J, Ramirez C, Runzer-Colmenares FM et al.. “Effects of a gait training program with the Fisior® sequential square mat on balance and gait in patients with Parkinson's disease: a randomized clinical trial.” BMC complementary medicine and therapies (2026). PMID: 41555326 ↗
L1bCited in: Supportive Care and Complication Management - [204]
Garcez PA, DeJesus BM, Oliveira LR et al.. “Effect of transcutaneous electrical nerve stimulation associated to exercise for pain in Parkinson's disease: a randomized crossover clinical trial.” Pain management (2026). PMID: 42083446 ↗
L1bCited in: Supportive Care and Complication Management - [205]
Karabacak A, Gezer Karabacak T, Özen Barut B. “Efficacy of Suprascapular Nerve Block and Pulsed Radiofrequency for Chronic Shoulder Pain in Parkinson's Disease.” Pain research & management (2026). PMID: 42213538 ↗
L2bCited in: Supportive Care and Complication Management - [206]
Shaikh AG, Antoniades C, Arshad Q et al.. “Multimodal mapping of balance dysfunction in Parkinson's disease: a consensus roadmap for research and intervention.” Current opinion in neurology (2026). PMID: 42307076 ↗
L1cCited in: Guidelines and Resources - [207]
Ory Magne F, Drapier S, Marques AR et al.. “A delphi consensus statement about French practical management of continuous apomorphine infusion in patients with Parkinson's disease and motor fluctuations.” Parkinsonism & related disorders (2025). PMID: 40413152 ↗
L1cCited in: Guidelines and Resources - [208]
Buhmann C, Kalbe E, Claus I et al.. “Parkinson´s day-clinic: which patients should be selected and what services should be offered for successful therapy?” Journal of neural transmission (Vienna, Austria : 1996) (2025). PMID: 40299066 ↗
L1cCited in: Guidelines and Resources - [209]
Rodrigues AM, Costa C, Gago M et al.. “Expert perspectives on the use of safinamide for Parkinson's disease in Portugal: insights from a Portuguese Delphi Consensus.” Journal of comparative effectiveness research (2025). PMID: 40474741 ↗
L1cCited in: Guidelines and Resources - [210]
Popławska-Domaszewicz K, Siuda J, Rudzińska-Bar M et al.. “Challenges of equitable access to device-aided therapies for advanced Parkinson's Disease in Poland - expert consensus and treatment recommendations.” Neurologia i neurochirurgia polska (2024). PMID: 39737586 ↗
L1cCited in: Guidelines and Resources - [211]
Xu J, Xu X, Guo X et al.. “Improving reliability of movement assessment in Parkinson's disease using computer vision-based automated severity estimation.” Journal of Parkinson's disease (2025). PMID: 39973505 ↗
L2bCited in: Guidelines and Resources - [212]
Trundell D, Davies EW, Barrett L et al.. “Estimation of and clinical consensus on the meaningful motor progression threshold on MDS-UPDRS Part III.” Journal of Parkinson's disease (2025). PMID: 39973477 ↗
L2bCited in: Guidelines and Resources